What Is Cagrilintide? The Emerging Weight Loss Peptide Explained
Peptides · Cagrilintide
What Is Cagrilintide? The Emerging Weight Loss Peptide
A closer look at the long acting amylin analogue being studied for appetite regulation, metabolic signaling, and sustained weight loss.
The amylin signal after a meal
- AmylinReleased with insulin
- BrainFewer hunger signals
- StomachSlower emptying
- Blood sugarHelps regulate levels
Dashed line: cagrilintide, a long acting amylin analogue given once weekly.
The Short Version
- Cagrilintide is a long acting amylin analogue being studied for appetite regulation, metabolic signaling, and sustained weight loss.
- It activates amylin and calcitonin receptors, a different pathway than GLP-1 medications like semaglutide.
- Because of its long acting design, it can be given as a once weekly injection, more convenient than daily medications.
- Combined with semaglutide, cagrilintide has produced greater weight loss results than semaglutide alone, including in the large phase 3 REDEFINE 1 trial.
This article is part of our Complete Peptides Guide, where we explore the science behind BPC-157, GHK-CU, and GLP-1 research peptides. Cagrilintide is an emerging weight loss peptide that has generated significant attention in the field of obesity treatment. Classified as a long acting amylin analogue, this experimental medication is being studied for its ability to regulate appetite, improve metabolic signaling, and promote sustained weight loss. If you're exploring different medications and peptides used for metabolic health and fat loss, you may also want to read Best Ozempic Alternatives: GLP-1 Drugs and Peptides for Weight Loss.
02Amylin
Understanding Cagrilintide
Cagrilintide belongs to a class of compounds known as amylin analogues, which mimic the hormone amylin.
Mimicking a Natural Hormone
What it means
- 1Amylin is naturally released alongside insulin
- 2It plays a role in regulating appetite and digestion
- 3Cagrilintide was designed to enhance these natural processes
Convenience: because of its long acting design, cagrilintide can be administered as a once weekly injection, making it convenient compared to some daily medications used for weight management.
03How it works
How Cagrilintide Works
Cagrilintide works by activating amylin receptors and calcitonin receptors, a different pathway than GLP-1 medications.
Amylin & calcitonin receptors
Key Mechanisms
Includes
- Reducing hunger signals in the brain
- Slowing gastric emptying
- Increasing feelings of fullness after meals
- Helping regulate blood sugar levels
Research on how cagrilintide binds amylin and calcitonin receptors: NCBI, PMC11982234
Go deeper: see Semaglutide vs Retatrutide: Which GLP-1 Weight Loss Drug Works Better? to understand how GLP-1 medications compare.
04Trials
Clinical Trials and Weight Loss Results
Cagrilintide has shown encouraging results in several clinical trials studying weight loss and metabolic health. In a randomized phase 2 study of 706 adults, participants were given varying weekly doses of cagrilintide over a 26 week treatment period.
Body weight
Significant reductions in body weight, with higher doses producing greater results, a clear dose dependent response.
Waist circumference
Researchers observed decreases in waist circumference alongside weight loss.
Metabolic markers
Triglycerides fell in the cagrilintide groups, while blood sugar measures changed little in these participants without diabetes.
- Phase 2 · 2021Cagrilintide on its own
706 adults, 26 weeks. Average weight loss of 6.0 to 10.8 percent across doses, compared with 3.0 percent with placebo.
- Phase 3 · 2025With semaglutide (CagriSema)
REDEFINE 1: 3,417 adults, 68 weeks. 20.4 percent average weight loss, compared with 14.9 percent with semaglutide alone.
- Regulatory review · 2026Not approved yet
Novo Nordisk submitted CagriSema to the FDA in December 2025, and a US decision is expected in late 2026. Cagrilintide on its own is still in phase 3 trials.
Established in clinical trials
- Weekly cagrilintide lowered body weight more than placebo in randomized trials.
- Adding cagrilintide to semaglutide produced more weight loss than semaglutide alone in a phase 3 trial.
- Gastrointestinal effects such as nausea were the most common side effects.
Still being studied
- Long term safety and outcomes beyond the trial periods.
- Whether cagrilintide on its own will be approved; its phase 3 trials are still running.
- Approval of the combination, which is under FDA review.
Clinical trial data on cagrilintide and weight loss outcomes: PubMed, 34798060. In the larger phase 3 REDEFINE 1 trial (3,417 adults, 68 weeks, with lifestyle support in every group), people who received cagrilintide and semaglutide together lost 20.4 percent of their body weight on average, compared with 14.9 percent with semaglutide alone, 11.5 percent with cagrilintide alone and 3.0 percent with placebo: PubMed, 40544433.
05With semaglutide
Cagrilintide and Semaglutide: A Powerful Combination
Because these compounds act through different hormonal pathways, they may work synergistically to enhance weight loss.
Semaglutide
Activates the GLP-1 receptor, which reduces appetite and improves insulin regulation.
Cagrilintide
Activates amylin receptors, which further suppress hunger and slow digestion.
This combination strategy is being explored as a next generation approach to obesity treatment. See Cagrilintide + Semaglutide Stack Guide (CagriSema) for the full breakdown.
06Safety
Safety and Potential Side Effects
Clinical trials, including phase 3, indicate that cagrilintide is generally well tolerated, although gastrointestinal side effects are common.
Common side effects
Gastrointestinal symptoms such as nausea, constipation, and diarrhea, typically mild to moderate.
Adjustment period
Side effects often decrease as the body adjusts to treatment over time.
Ongoing research
Because cagrilintide is still being studied, long term safety data continues to be collected.
07Quick answers
Frequently Asked Questions
01What is Cagrilintide used for?
02Is Cagrilintide approved by the FDA?
03How does Cagrilintide help with weight loss?
04Can Cagrilintide be combined with Semaglutide?
05What are the side effects of Cagrilintide?
06Is Cagrilintide similar to GLP-1 medications?
Conclusion
Cagrilintide represents a promising new development in the treatment of obesity and metabolic disease. As a long acting amylin analogue, it offers a different approach to weight loss compared with traditional GLP-1 medications. By influencing appetite regulation, digestion, and metabolic signaling, cagrilintide may help individuals achieve meaningful and sustained reductions in body weight. Perhaps most exciting is its potential synergy with GLP-1 drugs like semaglutide, which could lead to even more effective treatment strategies in the future. While additional research is still underway, clinical trials so far suggest that cagrilintide may become an important tool in the growing field of metabolic medicine.
+Go deeper
Explore the Peptides Guide
Complete Peptides Guide: BPC-157, GHK-CU, GLP-1
Cagrilintide + Semaglutide Stack Guide (CagriSema)
Semaglutide vs Retatrutide: Which GLP-1 Weight Loss Drug Works Better?
Best Ozempic Alternatives: GLP-1 Drugs and Peptides for Weight Loss
What Is GHK-CU? The Copper Peptide Explained
GHK-CU Benefits for Skin Repair, Hair Growth, and Anti Aging
Injectable vs Topical GHK-CU: Which Form Works Best?
How Injectable GHK-CU Stimulates Collagen Production
What Is BPC-157? Benefits of the Healing Peptide for Recovery
BPC-157 Mechanism of Action: How This Healing Peptide Repairs Tissue
BPC-157 for Gut Healing and Leaky Gut
Oral BPC-157 Benefits: Gut Healing, Recovery & Usage Guide
+Keep reading
You May Also Like
Cagrilintide + Semaglutide Stack Guide (CagriSema)
Semaglutide vs Retatrutide: Which GLP-1 Weight Loss Drug Works Better?
Best Ozempic Alternatives: GLP-1 Drugs and Peptides for Weight Loss
Cagrilintide is one of the most promising amylin analogues in modern weight loss research, especially in combination with GLP-1 medications.
For educational purposes only. Nothing here is medical advice, consult a qualified professional before starting any new peptide or medication.